JP2015507625A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015507625A5 JP2015507625A5 JP2014548964A JP2014548964A JP2015507625A5 JP 2015507625 A5 JP2015507625 A5 JP 2015507625A5 JP 2014548964 A JP2014548964 A JP 2014548964A JP 2014548964 A JP2014548964 A JP 2014548964A JP 2015507625 A5 JP2015507625 A5 JP 2015507625A5
- Authority
- JP
- Japan
- Prior art keywords
- antisense compound
- modified
- malat
- compound according
- cancer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 230000000692 anti-sense Effects 0.000 claims 21
- 150000001875 compounds Chemical class 0.000 claims 21
- 239000002777 nucleoside Substances 0.000 claims 6
- 229920000272 Oligonucleotide Polymers 0.000 claims 5
- 108020004707 nucleic acids Proteins 0.000 claims 5
- 150000007523 nucleic acids Chemical class 0.000 claims 5
- 201000011510 cancer Diseases 0.000 claims 3
- 150000003833 nucleoside derivatives Chemical class 0.000 claims 3
- 125000003835 nucleoside group Chemical group 0.000 claims 3
- 125000002619 bicyclic group Chemical group 0.000 claims 2
- 230000000295 complement Effects 0.000 claims 2
- 229920000160 (ribonucleotides)n+m Polymers 0.000 claims 1
- LRSASMSXMSNRBT-UHFFFAOYSA-N 5-Methylcytosine Chemical group CC1=CNC(=O)N=C1N LRSASMSXMSNRBT-UHFFFAOYSA-N 0.000 claims 1
- 208000010507 Adenocarcinoma of Lung Diseases 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 206010027476 Metastasis Diseases 0.000 claims 1
- 229920001850 Nucleic acid sequence Polymers 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 201000002313 intestinal cancer Diseases 0.000 claims 1
- 201000007270 liver cancer Diseases 0.000 claims 1
- 201000005249 lung adenocarcinoma Diseases 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 claims 1
- RYYWUUFWQRZTIU-UHFFFAOYSA-K thiophosphate Chemical compound [O-]P([O-])([O-])=S RYYWUUFWQRZTIU-UHFFFAOYSA-K 0.000 claims 1
Claims (15)
- 動物における原発性癌の治療に使用するためのアンチセンス化合物であって、該アンチセンス化合物が、肺腺癌内転移関連性転写物１（Metastasis-Associated-in-Lung-Adenocarcinoma-Transcript-1:ＭＡＬＡＴ−１）核酸に対して少なくとも８５％相補的である核酸塩基配列を有する１２〜３０個の連結したヌクレオシドから成る修飾オリゴヌクレオチドを含み、該アンチセンス化合物がＭＡＬＡＴ−１の発現を低減する、前記アンチセンス化合物。
- アンチセンス化合物が、
（ａ）ＭＡＬＡＴ−１ ＲＮＡ；又は
（ｂ）ＭＡＬＡＴ−１タンパク質、
の発現を低減する、請求項１に記載のアンチセンス化合物。 - ＭＡＬＡＴ−１核酸がヒトＭＡＬＡＴ−１核酸である、請求項１又は２に記載のアンチセンス化合物。
- ヒトＭＡＬＡＴ−１核酸が配列番号１のヌクレオチド配列を有する、請求項３に記載のアンチセンス化合物。
- 修飾オリゴヌクレオチドがヒトＭＡＬＡＴ−１核酸に対して１００％相補的である、請求項１〜４のいずれか１項に記載のアンチセンス化合物。
- アンチセンス化合物が、原発性癌の増殖を阻害する、請求項１〜５のいずれか１項に記載のアンチセンス化合物。
- 原発性癌が、結腸癌、肺癌、肝臓癌、前立腺癌、又は腸癌である、請求項１〜６のいずれか１項に記載のアンチセンス化合物。
- アンチセンス化合物が一本鎖オリゴヌクレオチドである、請求項１〜７のいずれか１項に記載のアンチセンス化合物。
- 修飾オリゴヌクレオチドが少なくとも１つの修飾ヌクレオシド間結合を含み、場合により修飾ヌクレオシド間結合がホスホロチオエートヌクレオシド間結合である、請求項１〜８のいずれか１項に記載のアンチセンス化合物。
- 少なくとも１つのヌクレオシドが、修飾された糖を含む、請求項１〜９のいずれか１項に記載のアンチセンス化合物。
- 修飾された糖が二環式糖であり、場合により二環式糖が４’−ＣＨ（ＣＨ３）−Ｏ−２’架橋、４’−（ＣＨ２）−Ｏ−２’架橋、または４’−（ＣＨ２）２−Ｏ−２’架橋を含む、請求項１０に記載のアンチセンス化合物。
- 修飾された糖が２’−Ｏ−メトキシエチル基を含む、請求項１０に記載のアンチセンス化合物。
- 少なくとも１つのヌクレオシドが、修飾された核酸塩基を含む、請求項１〜１２のいずれか１項に記載のアンチセンス化合物。
- 修飾された核酸塩基が５−メチルシトシンである、請求項１３に記載のアンチセンス化合物。
- 修飾オリゴヌクレオチドが、
連結したデオキシヌクレオシドから成るギャップセグメント；
連結したヌクレオシドから成る５’ウィングセグメント；及び
連結したヌクレオシドから成る３’ウィングセグメントを含み、ギャップセグメントは５’ウィングセグメントおよび３’ウィングセグメントに直接隣接してそれらの間に位置しており、各ウィングセグメントの各ヌクレオシドは修飾された糖を含む、
請求項１〜１４のいずれか１項に記載のアンチセンス化合物。
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161579343P | 2011-12-22 | 2011-12-22 | |
| US61/579,343 | 2011-12-22 | ||
| PCT/US2012/071371 WO2013096837A1 (en) | 2011-12-22 | 2012-12-21 | Methods for modulating metastasis-associated-in-lung-adenocarcinoma-transcript-1(malat-1) expression |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2015507625A JP2015507625A (ja) | 2015-03-12 |
| JP2015507625A5 true JP2015507625A5 (ja) | 2016-02-18 |
| JP6280045B2 JP6280045B2 (ja) | 2018-02-14 |
Family
ID=48669557
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014548964A Active JP6280045B2 (ja) | 2011-12-22 | 2012-12-21 | 肺腺癌内転移関連性転写物１（ｍｅｔａｓｔａｓｉｓ−ａｓｓｏｃｉａｔｅｄ−ｉｎ−ｌｕｎｇ−ａｄｅｎｏｃａｒｃｉｎｏｍａ−ｔｒａｎｓｃｒｉｐｔ−１：ｍａｌａｔ−１）の発現調節法 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US9546368B2 (ja) |
| EP (1) | EP2794880B1 (ja) |
| JP (1) | JP6280045B2 (ja) |
| AU (1) | AU2012358238B2 (ja) |
| CA (1) | CA2859729C (ja) |
| DK (1) | DK2794880T3 (ja) |
| ES (1) | ES2673960T3 (ja) |
| WO (1) | WO2013096837A1 (ja) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201322034D0 (en) | 2013-12-12 | 2014-01-29 | Almac Diagnostics Ltd | Prostate cancer classification |
| USRE48856E1 (en) | 2014-02-07 | 2021-12-21 | Vib Vzw | Inhibition of NEAT1 for treatment of solid tumors |
| WO2016073828A1 (en) * | 2014-11-06 | 2016-05-12 | Ibis Biosciences, Inc. | Malat-1, a non-coding rna, is a target for the regulation of learning and memory |
| US20190192576A1 (en) * | 2016-08-30 | 2019-06-27 | University Of South Florida | Adipose derived stem cell exosomes and uses thereof |
| AU2017368050A1 (en) | 2016-11-29 | 2019-06-20 | Puretech Lyt, Inc. | Exosomes for delivery of therapeutic agents |
| US10626165B2 (en) | 2016-12-14 | 2020-04-21 | Janssen Biotech, Inc. | CD8a-binding fibronectin type III domains |
| WO2018111978A1 (en) | 2016-12-14 | 2018-06-21 | Janssen Biotech, Inc. | Cd137 binding fibronectin type iii domains |
| EP3554535A4 (en) | 2016-12-14 | 2020-10-21 | Janssen Biotech, Inc. | PD-L1 BINDING FIBRONECTIN TYPE III DOMAINS |
| US11359200B2 (en) * | 2017-04-09 | 2022-06-14 | The Cleveland Clinic Foundation | Cancer treatment by MALAT1 inhibition |
| US20190184028A1 (en) * | 2017-12-14 | 2019-06-20 | Janssen Biotech, Inc. | Targeting with firbronectin type iii like domain molecules |
| BR112021002779A2 (pt) | 2018-08-15 | 2021-05-04 | Illumina, Inc. | composições e métodos para melhorar o enriquecimento de bibliotecas |
| EP3931328A4 (en) * | 2019-02-27 | 2023-09-13 | Ionis Pharmaceuticals, Inc. | MODULATORS OF MALAT1 EXPRESSION |
| US11628222B2 (en) | 2019-10-14 | 2023-04-18 | Aro Biotherapeutics Company | CD71 binding fibronectin type III domains |
| WO2021076574A2 (en) | 2019-10-14 | 2021-04-22 | Aro Biotherapeutics Company | Fn3 domain-sirna conjugates and uses thereof |
| EP4229202A1 (en) * | 2020-10-13 | 2023-08-23 | The Brigham & Women's Hospital, Inc. | Compositions and methods targeting circ2082 for the treatment of cancer |
| US20240141340A1 (en) | 2021-03-05 | 2024-05-02 | Proqr Therapeutics Ii B.V. | Antisense oligonucleotides for use in the treatment of corneal dystrophies |
Family Cites Families (64)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2699808A (en) | 1944-10-06 | 1955-01-18 | Mark W Lowe | Apparatus for peeling tomatoes |
| US2699508A (en) | 1951-12-21 | 1955-01-11 | Selectronics Inc | Method of mounting and construction of mounting for low frequency piezoelectric crystals |
| US5118800A (en) | 1983-12-20 | 1992-06-02 | California Institute Of Technology | Oligonucleotides possessing a primary amino group in the terminal nucleotide |
| FR2567892B1 (fr) | 1984-07-19 | 1989-02-17 | Centre Nat Rech Scient | Nouveaux oligonucleotides, leur procede de preparation et leurs applications comme mediateurs dans le developpement des effets des interferons |
| US5506337A (en) | 1985-03-15 | 1996-04-09 | Antivirals Inc. | Morpholino-subunit combinatorial library and method |
| US5185444A (en) | 1985-03-15 | 1993-02-09 | Anti-Gene Deveopment Group | Uncharged morpolino-based polymers having phosphorous containing chiral intersubunit linkages |
| US5166315A (en) | 1989-12-20 | 1992-11-24 | Anti-Gene Development Group | Sequence-specific binding polymers for duplex nucleic acids |
| US5034506A (en) | 1985-03-15 | 1991-07-23 | Anti-Gene Development Group | Uncharged morpholino-based polymers having achiral intersubunit linkages |
| US5591722A (en) | 1989-09-15 | 1997-01-07 | Southern Research Institute | 2'-deoxy-4'-thioribonucleosides and their antiviral activity |
| EP0942000B1 (en) | 1989-10-24 | 2004-06-23 | Isis Pharmaceuticals, Inc. | 2'-Modified oligonucleotides |
| US5646265A (en) | 1990-01-11 | 1997-07-08 | Isis Pharmceuticals, Inc. | Process for the preparation of 2'-O-alkyl purine phosphoramidites |
| US5670633A (en) | 1990-01-11 | 1997-09-23 | Isis Pharmaceuticals, Inc. | Sugar modified oligonucleotides that detect and modulate gene expression |
| GB9009980D0 (en) | 1990-05-03 | 1990-06-27 | Amersham Int Plc | Phosphoramidite derivatives,their preparation and the use thereof in the incorporation of reporter groups on synthetic oligonucleotides |
| EP0455905B1 (en) | 1990-05-11 | 1998-06-17 | Microprobe Corporation | Dipsticks for nucleic acid hybridization assays and methods for covalently immobilizing oligonucleotides |
| DE59208572D1 (de) | 1991-10-17 | 1997-07-10 | Ciba Geigy Ag | Bicyclische Nukleoside, Oligonukleotide, Verfahren zu deren Herstellung und Zwischenprodukte |
| US5359044A (en) | 1991-12-13 | 1994-10-25 | Isis Pharmaceuticals | Cyclobutyl oligonucleotide surrogates |
| FR2687679B1 (fr) | 1992-02-05 | 1994-10-28 | Centre Nat Rech Scient | Oligothionucleotides. |
| EP0577558A2 (de) | 1992-07-01 | 1994-01-05 | Ciba-Geigy Ag | Carbocyclische Nukleoside mit bicyclischen Ringen, Oligonukleotide daraus, Verfahren zu deren Herstellung, deren Verwendung und Zwischenproduckte |
| JPH08504559A (ja) | 1992-12-14 | 1996-05-14 | ハネウエル・インコーポレーテッド | 個別に制御される冗長巻線を有するモータシステム |
| ATE155467T1 (de) | 1993-03-30 | 1997-08-15 | Sanofi Sa | Acyclische nucleosid analoge und sie enthaltende oligonucleotidsequenzen |
| US5446137B1 (en) | 1993-12-09 | 1998-10-06 | Behringwerke Ag | Oligonucleotides containing 4'-substituted nucleotides |
| US5519134A (en) | 1994-01-11 | 1996-05-21 | Isis Pharmaceuticals, Inc. | Pyrrolidine-containing monomers and oligomers |
| US5627053A (en) | 1994-03-29 | 1997-05-06 | Ribozyme Pharmaceuticals, Inc. | 2'deoxy-2'-alkylnucleotide containing nucleic acid |
| US5597909A (en) | 1994-08-25 | 1997-01-28 | Chiron Corporation | Polynucleotide reagents containing modified deoxyribose moieties, and associated methods of synthesis and use |
| US5656408A (en) | 1996-04-29 | 1997-08-12 | Xerox Corporation | Coated carrier particles |
| JP3756313B2 (ja) | 1997-03-07 | 2006-03-15 | 武 今西 | 新規ビシクロヌクレオシド及びオリゴヌクレオチド類縁体 |
| US6770748B2 (en) | 1997-03-07 | 2004-08-03 | Takeshi Imanishi | Bicyclonucleoside and oligonucleotide analogue |
| US6794499B2 (en) | 1997-09-12 | 2004-09-21 | Exiqon A/S | Oligonucleotide analogues |
| CN1273476C (zh) | 1997-09-12 | 2006-09-06 | 埃克西康有限公司 | 寡核苷酸类似物 |
| US6043352A (en) | 1998-08-07 | 2000-03-28 | Isis Pharmaceuticals, Inc. | 2'-O-Dimethylaminoethyloxyethyl-modified oligonucleotides |
| BR0009884A (pt) | 1999-04-21 | 2002-01-08 | American Home Prod | Processos e composições para a inibição da função das sequências de polinucleotìdeos |
| NZ514348A (en) | 1999-05-04 | 2004-05-28 | Exiqon As | L-ribo-LNA analogues |
| US6525191B1 (en) | 1999-05-11 | 2003-02-25 | Kanda S. Ramasamy | Conformationally constrained L-nucleosides |
| ATE322493T1 (de) | 1999-12-30 | 2006-04-15 | Leuven K U Res & Dev | Cyclohexennukleinsäuren |
| CA2452458A1 (en) | 2001-07-03 | 2003-01-16 | Isis Pharmaceuticals, Inc. | Nuclease resistant chimeric oligonucleotides |
| JP2006500012A (ja) | 2002-07-31 | 2006-01-05 | ヌクレオニクス インコーポレーティッド | 二本鎖ｒｎａの構造および構築物、並びにその作製法および使用法 |
| US20060035344A1 (en) | 2002-10-18 | 2006-02-16 | Pachuk Catherine J | Double-stranded rna structures and constructs, and methods for generating and using the same |
| EP1562971B1 (en) | 2002-11-05 | 2014-02-12 | Isis Pharmaceuticals, Inc. | Polycyclic sugar surrogate-containing oligomeric compounds and compositions for use in gene modulation |
| AU2003290598A1 (en) | 2002-11-05 | 2004-06-03 | Isis Pharmaceuticals, Inc. | Modified oligonucleotides for use in rna interference |
| US6673661B1 (en) | 2002-12-20 | 2004-01-06 | Taiwan Semiconductor Manufacturing Co., Ltd. | Self-aligned method for forming dual gate thin film transistor (TFT) device |
| WO2004106356A1 (en) | 2003-05-27 | 2004-12-09 | Syddansk Universitet | Functionalized nucleotide derivatives |
| DK1661905T3 (da) | 2003-08-28 | 2012-07-23 | Takeshi Imanishi | Hidtil ukendte syntetiske nukleinsyrer af N-O-krydsbindingstype |
| JP5379347B2 (ja) | 2003-09-18 | 2013-12-25 | アイシス ファーマシューティカルズ， インコーポレーテッド | ４’−チオヌクレオシドおよびオリゴマー化合物 |
| JP2008501694A (ja) | 2004-06-03 | 2008-01-24 | アイシス ファーマシューティカルズ、インク． | 遺伝子調節の使用のために個別に修飾された鎖を有する二本鎖組成物 |
| WO2006047842A2 (en) | 2004-11-08 | 2006-05-11 | K.U. Leuven Research And Development | Modified nucleosides for rna interference |
| EP1951263A4 (en) | 2005-11-21 | 2009-11-18 | Johnson & Johnson Res Pty Ltd | MULTITARGETING DISTURBING RNAS WITH TWO ACTIVE STRANDS AND DESIGN AND APPLICATION METHODS |
| PL2314594T3 (pl) | 2006-01-27 | 2014-12-31 | Isis Pharmaceuticals Inc | Zmodyfikowane w pozycji 6 analogi bicykliczne kwasów nukleinowych |
| DK2066684T3 (da) | 2006-05-11 | 2012-10-22 | Isis Pharmaceuticals Inc | 5´-Modificerede bicycliske nukleinsyreanaloge |
| US20100190837A1 (en) | 2007-02-15 | 2010-07-29 | Isis Pharmaceuticals, Inc. | 5'-Substituted-2-F' Modified Nucleosides and Oligomeric Compounds Prepared Therefrom |
| ES2388590T3 (es) | 2007-05-30 | 2012-10-16 | Isis Pharmaceuticals, Inc. | Análogos de ácidos nucleicos bicíclicos con puente aminometileno N-sustituido. |
| ES2386492T3 (es) | 2007-06-08 | 2012-08-21 | Isis Pharmaceuticals, Inc. | Análogos de ácidos nucleicos bicíclicos carbocíclicos |
| ES2376507T5 (es) | 2007-07-05 | 2015-08-31 | Isis Pharmaceuticals, Inc. | Análogos de ácidos nucleicos bicíclicos 6-disustituidos |
| US8546556B2 (en) | 2007-11-21 | 2013-10-01 | Isis Pharmaceuticals, Inc | Carbocyclic alpha-L-bicyclic nucleic acid analogs |
| US8530640B2 (en) | 2008-02-07 | 2013-09-10 | Isis Pharmaceuticals, Inc. | Bicyclic cyclohexitol nucleic acid analogs |
| EP2356129B1 (en) | 2008-09-24 | 2013-04-03 | Isis Pharmaceuticals, Inc. | Substituted alpha-l-bicyclic nucleosides |
| US8604192B2 (en) | 2008-09-24 | 2013-12-10 | Isis Pharmaceuticals, Inc. | Cyclohexenyl nucleic acids analogs |
| AT507215B1 (de) | 2009-01-14 | 2010-03-15 | Boehler Edelstahl Gmbh & Co Kg | Verschleissbeständiger werkstoff |
| US20120021515A1 (en) | 2009-02-06 | 2012-01-26 | Swayze Eric E | Oligomeric compounds and methods |
| US9012421B2 (en) | 2009-08-06 | 2015-04-21 | Isis Pharmaceuticals, Inc. | Bicyclic cyclohexose nucleic acid analogs |
| WO2011130742A2 (en) | 2010-04-16 | 2011-10-20 | Wisconsin Alumni Research Foundation | Diagnostic evaluation of antibody responses to commonly recognized prostate cancer-associated antigens |
| CN103154014B (zh) | 2010-04-28 | 2015-03-25 | Isis制药公司 | 修饰核苷、其类似物以及由它们制备的寡聚化合物 |
| EP3633038A3 (en) | 2010-07-19 | 2020-07-29 | Ionis Pharmaceuticals, Inc. | Modulation of dystrophia myotonica-protein kinase (dmpk) expression |
| US9984408B1 (en) | 2012-05-30 | 2018-05-29 | Amazon Technologies, Inc. | Method, medium, and system for live video cooperative shopping |
| US9778708B1 (en) | 2016-07-18 | 2017-10-03 | Lenovo Enterprise Solutions (Singapore) Pte. Ltd. | Dual sided latching retainer for computer modules |
-
2012
- 2012-12-21 EP EP12860563.1A patent/EP2794880B1/en active Active
- 2012-12-21 AU AU2012358238A patent/AU2012358238B2/en active Active
- 2012-12-21 DK DK12860563.1T patent/DK2794880T3/en active
- 2012-12-21 ES ES12860563.1T patent/ES2673960T3/es active Active
- 2012-12-21 WO PCT/US2012/071371 patent/WO2013096837A1/en active Application Filing
- 2012-12-21 US US14/368,269 patent/US9546368B2/en active Active
- 2012-12-21 JP JP2014548964A patent/JP6280045B2/ja active Active
- 2012-12-21 CA CA2859729A patent/CA2859729C/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2015507625A5 (ja) | ||
| JP2016116520A5 (ja) | ||
| JP2013226147A5 (ja) | ||
| JP2014511686A5 (ja) | ||
| HRP20200042T1 (hr) | Suprotne nukleinske kiseline za uporabu u liječenju duchennove mišićne distrofije | |
| HRP20191232T1 (hr) | Inhibicija, posredovana rna interferencijom, ekspresije gena virusa hepatitisa b (hbv) korištenjem kratkih interferirajućih nukleinskih kiselina (sina) | |
| HRP20201426T1 (hr) | Postupci i pripravci za moduliranje ekspresije apolipoproteina (a) | |
| JP2016501513A5 (ja) | ||
| JP2012505660A5 (ja) | ||
| JP2011501962A5 (ja) | ||
| JP2016171800A5 (ja) | ||
| EA201200217A1 (ru) | Рнк с комбинацией из немодифицированных и модифицированных нуклеотидов для экспрессии белков | |
| JP2018512041A5 (ja) | ||
| JP2017510271A5 (ja) | ||
| JP2018512110A5 (ja) | ||
| JP2017505623A5 (ja) | ||
| NZ616512A (en) | Modulation of hepatitis b virus (hbv) expression | |
| JP2015502365A5 (ja) | ||
| JP2014521310A5 (ja) | ||
| RU2016140897A (ru) | Композиции для модуляции экспрессии атаксина 2 | |
| JP2014527401A5 (ja) | ||
| JP2012050438A5 (ja) | ||
| JP2012029693A5 (ja) | ||
| JP2015142558A5 (ja) | ||
| JP2016528891A5 (ja) |